MoonLake Immunotherapeutics Prices $200M Public Offering at $20.00 Per Share

summarizeSummary

MoonLake Immunotherapeutics has priced its public offering, raising approximately $200 million through the sale of Class A Ordinary Shares and pre-funded warrants at $20.00 per share, securing funding for its lead asset's development and commercialization.

check_boxKey Events

• Offering Priced and Finalized

  Finalizes the terms and pricing of a public offering, selling 9,000,000 Class A Ordinary Shares and pre-funded warrants to purchase up to 1,000,000 Class A Ordinary Shares at $20.00 per share.

• Significant Capital Raise

  The offering is expected to generate approximately $188.8 million in net proceeds, potentially increasing to $217.1 million if the underwriters fully exercise their option to purchase an additional 1,500,000 shares.

• Dilution for Existing Shareholders

  The offering represents a potential dilution of approximately 13.4% to 15.4% for existing shareholders, based on shares outstanding prior to this offering.

• Extended Cash Runway

  Proceeds, combined with existing cash, are expected to fund operations and capital expenditures until mid-2028, supporting the anticipated 2027 commercial launch of sonelokimab.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of the public offering initiated on June 22, 2026. MoonLake Immunotherapeutics is raising approximately $200 million (potentially up to $230 million if the underwriters' option is fully exercised) through the sale of Class A Ordinary Shares and pre-funded warrants. This capital raise is crucial for funding the research, development, and commercialization activities of its lead asset, sonelokimab, extending the company's operational runway to mid-2028. The offering follows highly positive Phase 3 clinical trial results for sonelokimab, and while dilutive for existing shareholders, it secures essential funding to advance the drug towards its anticipated 2027 commercial launch.